



Bacterial Carbohydrate and Protein Vaccine Research

Guest Editors:

Dr. Vana Spoulou

School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Prof. John Routsias

Department of Microbiology, Athens Medical School, 11527 Athens, Greece

Deadline for manuscript submissions:

closed (30 April 2022)

Message from the Guest Editors

Dear Colleagues,

Vaccines are one of the most cost-effective way to control infectious diseases. Protein vaccines are composed of purified or recombinant proteinaceous antigens from a pathogen, such as a bacterium or virus. In addition to protein antigens, cell surface carbohydrates are widely used as antigenic components of vaccines. Glycoconjugate vaccines are composed of carbohydrate antigens, covalently linked to a carrier moiety, usually a non-toxic protein.

This Special Issue focuses on protein vaccine and bacterial carbohydrate vaccine. Submission of original articles, systematic reviews, short communications, and other types of article on related topics are welcome. Manuscripts will follow standard Journal peer-review practices, and those accepted for publication will appear in the special issue on Bacterial Carbohydrate and Protein Vaccine Research. We look forward to receiving and welcome your contributions.

Keywords:

- Protein Vaccine
- Polysaccharide Vaccine
- Bacterial Carbohydrates
- Glycoconjugates
- Immunogens
- Peptide Antigens
- Vaccine Adjuvants





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com